Research Analysts’ Weekly Ratings Changes for Alexion Pharmaceuticals (ALXN)

Alexion Pharmaceuticals (NASDAQ: ALXN) recently received a number of ratings updates from brokerages and research firms:

  • 3/17/2018 – Alexion Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 3/16/2018 – Alexion Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $149.00 price target on the stock, up previously from $147.00.
  • 3/15/2018 – Alexion Pharmaceuticals had its price target raised by analysts at Nomura from $148.00 to $156.00. They now have a “buy” rating on the stock.
  • 3/15/2018 – Alexion Pharmaceuticals was given a new $160.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 3/15/2018 – Alexion Pharmaceuticals was given a new $161.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 3/9/2018 – Alexion Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $163.00 price target on the stock.
  • 3/1/2018 – Alexion Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 2/14/2018 – Alexion Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Alexion beat both earnings estimates and sales estimates in the fourth quarter. Alexion’s blockbuster drug, Soliris, continues to perform well and the FDA approval of the drug for generalized myasthenia gravis is likely to boost sales further. However, the company relies heavily on Soliris for growth and sales of the same will be impacted increased ALXN1210 trials. Pricing is also projected to hit revenues by 3% in 2018. Shares of the company have underperformed the industry over a year. Among new products, the company redefined its strategy for Kanuma as the drug lagged expectations. Meanwhile, in order to focus better in core areas, Alexion has de-prioritized a few clinical programs and terminated partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma.”
  • 2/12/2018 – Alexion Pharmaceuticals was given a new $172.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $148.00 to $151.00. They now have an “overweight” rating on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $177.00 to $180.00. They now have an “outperform” rating on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals had its price target lowered by analysts at Leerink Swann from $166.00 to $153.00. They now have an “outperform” rating on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $151.00 price target on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals was given a new $161.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 2/9/2018 – Alexion Pharmaceuticals had its price target lowered by analysts at Citigroup from $173.00 to $170.00. They now have a “buy” rating on the stock.
  • 2/5/2018 – Alexion Pharmaceuticals was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating.
  • 2/2/2018 – Alexion Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 1/18/2018 – Alexion Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Credit Suisse Group AG. They now have a $147.00 price target on the stock.

Alexion Pharmaceuticals stock traded down $4.72 during trading hours on Monday, hitting $122.03. The stock had a trading volume of 2,040,195 shares, compared to its average volume of 2,230,829. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a market capitalization of $28,098.12, a P/E ratio of 62.26, a price-to-earnings-growth ratio of 1.17 and a beta of 1.13. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10.

How to Become a New Pot Stock Millionaire

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. During the same period last year, the company earned $1.26 earnings per share. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current fiscal year.

In related news, SVP Heidi L. Wagner sold 655 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the sale, the senior vice president now directly owns 32,635 shares in the company, valued at $3,826,780.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Julie O’neill sold 1,625 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $119.83, for a total value of $194,723.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,253 shares of company stock valued at $3,656,229. Corporate insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply